Galectin Therapeutics, Inc. (GALT)
3.62
-0.09
(-2.43%)
USD |
NASDAQ |
Oct 16, 16:00
3.63
+0.01
(+0.28%)
After-Hours: 20:00
Galectin Therapeutics Research and Development Expense (Annual) : 14.29M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 14.29M |
| December 31, 2024 | 36.57M |
| December 31, 2023 | 32.13M |
| December 31, 2022 | 31.74M |
| December 31, 2021 | 23.82M |
| December 31, 2020 | 17.98M |
| December 31, 2019 | 7.467M |
| December 31, 2018 | 6.471M |
| December 31, 2017 | 11.72M |
| December 31, 2016 | 15.32M |
| December 31, 2015 | 13.11M |
| December 31, 2014 | 8.425M |
| December 31, 2013 | 5.688M |
| Date | Value |
|---|---|
| December 31, 2012 | 4.527M |
| December 31, 2011 | 3.552M |
| December 31, 2010 | 1.066M |
| December 31, 2009 | 1.11M |
| December 31, 2008 | 1.774M |
| December 31, 2007 | 2.053M |
| December 31, 2006 | 3.019M |
| December 31, 2005 | 3.04M |
| December 31, 2004 | 3.042M |
| December 31, 2003 | 1.950M |
| December 31, 2002 | 1.483M |
| December 31, 2001 | 0.8935M |
| December 31, 2000 | 0.1003M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Mirum Pharmaceuticals, Inc. | 185.83M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |